Kathleen Arnold
Acute Care · Ocean Springs, MSNPI 1134107139
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.7%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Lilly USA, LLC at 48.4% of the total. Among acute care clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,277 payments — averaging $170.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$105K
- Abbott$41K
- Tandem Diabetes Care, Inc.$24K
- Novo Nordisk$23K
- Sanofi-aventis U.S. LLC$9K
- Dexcom, Inc.$5K
- plus $10K from 26 others
What the payments were for
- Consulting fees$33,22015%
- Speaking & faculty fees$127,48259%
- Travel & lodging$37,06817%
- Food & beverage$19,2279%
- Education$630%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 398 | $105,118 |
| Abbott | 210 | $41,176 |
| Tandem Diabetes Care, Inc. | 53 | $24,488 |
| Novo Nordisk | 204 | $23,195 |
| Sanofi-aventis U.S. LLC | 78 | $8,748 |
| Dexcom, Inc. | 52 | $4,737 |
| Insulet Corporation | 18 | $2,127 |
| Medtronic | 26 | $1,417 |
| Novo Nordisk AS | 1 | $920 |
| Xeris Pharmaceuticals, Inc. | 46 | $789 |
| AstraZeneca | 31 | $721 |
| Bayer | 33 | $706 |
| Boehringer Ingelheim | 36 | $706 |
| Corcept Therapeutics | 14 | $441 |
| Renalytix AI, Inc. | 15 | $290 |
| Senseonics, Incorporated | 1 | $240 |
| Lifescan, Inc. | 14 | $229 |
| Sequel Med Tech, LLC | 7 | $177 |
| Zealand Pharma US, Inc. | 8 | $146 |
| Mannkind Corporation | 6 | $137 |
| GRT US Holding, Inc. | 3 | $108 |
| Merck | 5 | $103 |
| Janssen Scientific Affairs, LLC | 2 | $73 |
| Embecta Corp. | 3 | $59 |
| Ascensia Diabetes Care US Inc. | 3 | $52 |
| Averitas Pharma Inc. | 1 | $40 |
| BD | 2 | $40 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Cequr Corporation | 2 | $34 |
| Bard Peripheral Vascular, Inc. | 1 | $29 |
| Amphastar Pharmaceuticals, Inc. | 1 | $19 |
| Pfizer | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$51,989
- t:slim X2 Insulin Pump with Control-IQ$24,355
- FREESTYLE LIBRE 3$20,676
- TRULICITY$19,400
- RYBELSUS$11,317
- FreeStyle Libre 2$9,847
- FreeStyle Libre Pro$6,750
- Ozempic$5,710
- TZIELD$4,600
- DEXCOM G7 GSS (161)$3,739
- Omnipod$1,739
- FreeStyle Libre$1,475
- Tresiba$920
- INPEN SMART INSULIN DELIVERY SYSTEM$402
- InPen$319
- Eversense$240
- FARXIGA$237
- Korlym$231
- JARDIANCE$215
- Saxenda$114
How this compares
$217,119 in reported general payments places this provider in the 95th percentile of 223 acute care providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 204 | $334,264 |
| OzempicSemaglutide | 191 | $271,284 |
| JardianceEmpagliflozin | 250 | $244,405 |
| MounjaroTirzepatide | 178 | $236,538 |
| TrulicityDulaglutide | 110 | $141,116 |
| FarxigaDapagliflozin Propanediol | 128 | $130,511 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 74 | $97,861 |
| Tresiba Flextouch U-200Insulin Degludec | 74 | $68,668 |
| Tresiba Flextouch U-100Insulin Degludec | 82 | $62,132 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 54 | $61,082 |
| Xigduo XrDapaglifloz Propaned/Metformin | 44 | $45,014 |
| NovologInsulin Aspart | 86 | $41,868 |
| Novolog FlexpenInsulin Aspart | 117 | $39,524 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 41 | $36,853 |
| Humalog Kwikpen U-100Insulin Lispro | 63 | $29,736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskXultophy 100-3.6, Ozempic, Novolog | $23,195 | $647,417481 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $105,118 | $394,188337 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $706 | $281,258291 claims |
| AstraZenecaFarxiga | $721 | $130,511128 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $8,748 | $99,37488 claims |
| BayerKerendia | $706 | $17,36111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 223 acute care providers in Mississippi.
Other acute care in Ocean Springs
- Jamie DamicoOcean Springs$17K
- Amity ThompsonOcean Springs$5K
- Savannah McDanielOcean Springs$5K
- Paige PowellOcean Springs$3K
- Laresa NewtonOcean Springs$2K
- Christopher BellTupelo$348K
- Gavin GistOxford$42K
- Dylan BoydHattiesburg$15K
- Melinda ClarkStarkville$14K
- Michelle TaylorGulfport$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.